B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

PAK4

MOLECULAR TARGET

p21 (RAC1) activated kinase 4

UniProt: O96013NCBI Gene: 1029828 compounds

PAK4 (p21 (RAC1) activated kinase 4) is targeted by 28 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting PAK4

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1seliciclib4.91135
2tozasertib4.3375
3ruxolitinib4.2368
4nintedanib3.6136
5tae 6843.4330
6fedratinib3.4029
7purvalanola3.1823
8jnj 77066213.0921
9at 92833.0921
10lestaurtinib3.0420
11pf 037583093.0019
12r 4062.8316
13k 252a2.8316
14pf 005622712.7715
15crenolanib2.7114
16apitolisib2.7114
17kw 24492.6413
18gsk 6906932.6413
19defactinib2.4811
20azd 77622.309
21azd 14802.309
22su 0148132.208
23cyc 1162.087
24pf 038147351.795
25ucn 011.795
26alsterpaullone1.102
27kenpaullone1.102
28Axitinib0.691

About PAK4 as a Drug Target

PAK4 (p21 (RAC1) activated kinase 4) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 28 compounds with documented PAK4 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

PAK4 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.